Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Apr;60(4):705-10.
doi: 10.1002/pbc.24390. Epub 2012 Nov 14.

Early hematopoietic stem cell transplant is associated with favorable outcomes in children with MDS

Angela R Smith  1 , Ellen C Christiansen, John E Wagner, Qing Cao, Margaret L MacMillan, Heather E Stefanski, Barbara A Trotz, Michael J Burke, Michael R Verneris
Affiliations

Early hematopoietic stem cell transplant is associated with favorable outcomes in children with MDS

Angela R Smith et al. Pediatr Blood Cancer. 2013 Apr.

Abstract

Background: Although hematopoietic stem cell transplantation (HSCT) is the treatment of choice for childhood myelodysplastic syndrome (MDS), there is no consensus regarding patient or disease characteristics that predict outcomes.

Procedure: We reviewed 37 consecutive pediatric MDS patients who received myeloablative HSCT between 1990 and 2010 at a single center.

Results: Twenty had primary MDS and 17 had secondary MDS. Diagnostic cytogenetics included monosomy 7 (n = 21), trisomy 8 (n = 7) or normal/other (n = 8). According to the modified WHO MDS classification, thirty had refractory cytopenia and seven had refractory anemia with excess blasts. IPSS scores were: low risk (n = 1), intermediate-1 (n = 15), and intermediate-2 (n = 21). OS and DFS at 10 years in the entire cohort was 53% and 45%. Relapse at 10 years was 26% and 1 year TRM was 25%. In multivariate analysis, factors associated with improved 3 years DFS were not receiving pre-HSCT chemotherapy (RR = 0.30, 95% CI 0.10-0.88; P = 0.03) and a shorter interval (<140 days) from time of diagnosis to transplant (RR = 0.27, 95% CI 0.09-0.80; P = 0.02). Three years DFS in patients who did not receive pre-HSCT chemotherapy and those who had a shorter interval to transplant (n = 16) was 80%.

Conclusion: These results suggest that children with MDS should be referred for allogeneic HSCT soon after diagnosis and that pre-HSCT chemotherapy does not appear to improve outcomes.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Kaplan-Meier Analysis of Overall Survival and Disease Free Survival
A. Overall Survival. OS was 70% (95% CI 53–82%) at 1 year and 53% (95% CI 36–68%) at 3 years and beyond. B. Disease Free Survival and Relapse. DFS was 62% (95% CI 44–75%) at 1 year and 48% (95% CI 31–63%) at 3 years and 45% (95% CI 28–60%) at 10 years. The incidence of relapse was 20% (95% CI 7–33%) at 2 years and 26% (95% CI 11–41%) at 10 years.
Figure 1
Figure 1. Kaplan-Meier Analysis of Overall Survival and Disease Free Survival
A. Overall Survival. OS was 70% (95% CI 53–82%) at 1 year and 53% (95% CI 36–68%) at 3 years and beyond. B. Disease Free Survival and Relapse. DFS was 62% (95% CI 44–75%) at 1 year and 48% (95% CI 31–63%) at 3 years and 45% (95% CI 28–60%) at 10 years. The incidence of relapse was 20% (95% CI 7–33%) at 2 years and 26% (95% CI 11–41%) at 10 years.
Figure 2
Figure 2
A. Kaplan-Meier Analysis of 3-year DFS by Pre HSCT Chemotherapy Status. 3-year DFS was 60% (95% CI 40–75%) for patients who did not receive pre HSCT chemotherapy and 0% for patients who received pre HSCT chemotherapy (p<0.01). B. Kaplan-Meier Analysis of 3-year DFS by Time from Diagnosis to HSCT. 3-year DFS was 71% (95% CI 44–87%) in patients who had a diagnosis to HSCT time of <140 days and 26% (95% CI 10–47%) in those with diagnosis to HSCT time of ≥140 days (p<0.01). C. Kaplan-Meier Analysis of 3-year DFS in Patients who did not receive pre HSCT Chemotherapy and who were transplanted <140 days from Diagnosis. 3-year DFS was 80% (95% CI 51–93%) in the 16 patients who did not receive pre HSCT chemotherapy and were transplanted <140 days from diagnosis.
Figure 2
Figure 2
A. Kaplan-Meier Analysis of 3-year DFS by Pre HSCT Chemotherapy Status. 3-year DFS was 60% (95% CI 40–75%) for patients who did not receive pre HSCT chemotherapy and 0% for patients who received pre HSCT chemotherapy (p<0.01). B. Kaplan-Meier Analysis of 3-year DFS by Time from Diagnosis to HSCT. 3-year DFS was 71% (95% CI 44–87%) in patients who had a diagnosis to HSCT time of <140 days and 26% (95% CI 10–47%) in those with diagnosis to HSCT time of ≥140 days (p<0.01). C. Kaplan-Meier Analysis of 3-year DFS in Patients who did not receive pre HSCT Chemotherapy and who were transplanted <140 days from Diagnosis. 3-year DFS was 80% (95% CI 51–93%) in the 16 patients who did not receive pre HSCT chemotherapy and were transplanted <140 days from diagnosis.
Figure 2
Figure 2
A. Kaplan-Meier Analysis of 3-year DFS by Pre HSCT Chemotherapy Status. 3-year DFS was 60% (95% CI 40–75%) for patients who did not receive pre HSCT chemotherapy and 0% for patients who received pre HSCT chemotherapy (p<0.01). B. Kaplan-Meier Analysis of 3-year DFS by Time from Diagnosis to HSCT. 3-year DFS was 71% (95% CI 44–87%) in patients who had a diagnosis to HSCT time of <140 days and 26% (95% CI 10–47%) in those with diagnosis to HSCT time of ≥140 days (p<0.01). C. Kaplan-Meier Analysis of 3-year DFS in Patients who did not receive pre HSCT Chemotherapy and who were transplanted <140 days from Diagnosis. 3-year DFS was 80% (95% CI 51–93%) in the 16 patients who did not receive pre HSCT chemotherapy and were transplanted <140 days from diagnosis.
See this image and copyright information in PMC

References

    1. Smith FO, Woods WG. Myeloproliferative and myelodysplastic disorders. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. Lippincott Williams & Wilkins; Philadelphia: 2002. p. 615.
    1. Niemeyer C, Baumann I. Myelodysplastic syndrome in children and adolescents. Semin.Hematol. 2008;45:60–70. - PubMed
    1. Hasle H, Niemeyer CM, Chessells JM, et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia. 2003;17:277–282. - PubMed
    1. Hasle H. Myelodysplastic and myeloproliferative disorders in children. Curr Opin Pediatr. 2007;19:1–8. - PubMed
    1. Locatelli F, Zecca M, Pession A, Maserati E, De Stefano P, Severi F. Myelodysplastic syndromes: the pediatric point of view. Haematologica. 1995;80:268–279. - PubMed

Substances